Metropolitan Life Insurance Company (MetLife)’s Cue Biopharma CUE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-64	Closed	-$7K	–	2410
2023 Q2	$7K	Buy	+64	New	+$7.52K	﹤0.01%	2428
2022 Q1	–	Sell	-289	Closed	-$98.1K	–	2348
2021 Q4	$98.1K	Sell	289 -14	-5%	-$5.41K	﹤0.01%	2496
2021 Q3	$132K	Buy	303 +10	+3%	+$3.49K	﹤0.01%	2364
2021 Q2	$102K	Buy	293 +38	+15%	+$14.7K	﹤0.01%	2583
2021 Q1	$93.3K	Sell	255 -40	-14%	-$16.5K	﹤0.01%	2447
2020 Q4	$111K	Hold	295	–	–	﹤0.01%	2308
2020 Q3	$133K	Hold	295	–	–	﹤0.01%	2049
2020 Q2	$217K	Buy	295 +56	+23%	+$40.6K	﹤0.01%	1739
2020 Q1	$102K	Hold	239	–	–	﹤0.01%	2019
2019 Q4	$114K	Buy	+239	New	+$75.1K	﹤0.01%	2255

Other funds holding CUE

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CUE Position: Q3 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Cue Biopharma (CUE) in Q3 2023, closing a stake of 64 shares — an estimated $7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CUE in Q4 2019 and held it in 10 quarters. The position peaked at $217K in Q2 2020. 75 funds tracked by Wall St. Rank hold CUE as of Q3 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Cue Biopharma position as of Q3 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 64 Cue Biopharma shares in Q3 2023, an estimated $7K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Cue Biopharma in Q4 2019 and held it in 10 quarters.
Metropolitan Life Insurance Company (MetLife)'s Cue Biopharma position peaked at $217K in Q2 2020.
75 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.